( OTC-BB:SRNE,OTC-PINK:SRNE )

News from Sorrento Therapeutics, Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jan 12, 2015, 09:00 ET Sorrento Provides Status Update on the Cynviloq™ Registrational TRIBECA™ Study

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, announced...


Jan 06, 2015, 09:00 ET Conkwest, Sorrento And NantWorks Announce Presentation At The 33rd Annual J. P. Morgan Healthcare Conference By Dr. Patrick Soon-Shiong

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and Conkwest, Inc., an...


Jan 05, 2015, 09:00 ET Sorrento To Present At The 2015 Biotech Showcase And 8th Annual OneMedForum In San Francisco

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and...


Dec 19, 2014, 06:00 ET Sorrento and Conkwest Announce Exclusive Global Collaboration

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE;  Sorrento), an oncology company developing new treatments for cancer and associated pain, and...


Dec 15, 2014, 09:25 ET Sorrento Announces Strategic Investment By And Collaboration With Nantworks Founder Dr. Patrick Soon-Shiong For The Advancement Of Cancer Immunotherapies

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, announced today...


Dec 08, 2014, 09:15 ET Sorrento Therapeutics Announces Poster Presentations on its Anti-c-Met/PD-L1 Bispecific Antibodies and Anti-c-Met-Antibody Drug Conjugate at the 37th Annual San Antonio Breast Cancer Symposium

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated...


Dec 03, 2014, 09:30 ET Sorrento To Present At The 2014 Oppenheimer Healthcare Conference

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, today announced...


Nov 12, 2014, 11:00 ET Sorrento To Present At The 2014 Stifel Healthcare Conference

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), today announced that Dr. Henry Ji, President and Chief Executive Officer, will present...


Oct 15, 2014, 16:17 ET Les données pharmacocinétiques initiales de l'étude TRIBECA confirment le potentiel de bioéquivalence entre Cynviloq et le paclitaxel lié à de l'albumine

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), une société de produits oncologiques développant de nouveaux traitements...


Oct 15, 2014, 07:55 ET Erste pharmakokinetische Daten aus TRIBECA-Studie stützen potenzielle Bioäquivalenz zwischen Cynviloq und Albumin-gebundenem Paclitaxel

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), ein Onkologieunternehmen, das neue Behandlungsmethoden für Krebs sowie für die...


Oct 14, 2014, 16:00 ET Initial Pharmacokinetic Data From TRIBECA Study Support Potential For Bioequivalence Between Cynviloq And Albumin-Bound Paclitaxel

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain,...


Oct 03, 2014, 14:41 ET Sorrento and Lee's Pharmaceutical Enter into Exclusive China Licensing Agreement to Develop and Commercialize Anti-PD-L1 antibody

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its...


Sep 05, 2014, 08:45 ET Sorrento Therapeutics to Present at Two Healthcare Conferences

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its...


Aug 26, 2014, 08:45 ET Sorrento Awarded NIH Grant to Advance Immunotherapy Targeting Idiopathic Pulmonary Fibrosis (IPF)

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its...


Aug 18, 2014, 07:45 ET Data Published by Researchers from The Scripps Research Institute Demonstrate Potential for MYC Inhibitor Licensed by Sorrento Therapeutics

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its...


Aug 08, 2014, 17:00 ET Sorrento Therapeutics Appoints Douglas Ebersole to its Board of Directors

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its...


Jul 31, 2014, 17:38 ET Sorrento Announces the Unexpected Death of its Chief Business Officer

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) today announced the death of Mr. Amar Singh, Chief Business Officer and Executive Vice...


Jul 21, 2014, 08:45 ET Sorrento Awarded Grant from the National Institutes of Health for the Development of a Small Molecule Myc Inhibitor

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its...


Jul 01, 2014, 08:45 ET Sorrento Awarded up to $2.6 Million from the National Institutes of Health (NIH) for the Development of New Anti-bacterial Bispecific Antibodies and Antibody Formulated Drug Conjugates

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its...


Jun 25, 2014, 08:45 ET Morphotek and Sorrento Therapeutics Sign an Exclusive Research and Option Agreement to Generate and Develop Morphotek Antibody Drug Conjugates

Concortis Biosystems, Inc. (Concortis), a subsidiary of Sorrento Therapeutics (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company...